April 24, 2018 / 11:12 AM / 5 months ago

BRIEF-Checkmate Pharmaceuticals Announces Start Of Phase 1B Trial Of CMP-001 In Combination With Anti-Pd-L1 Immunotherapy In Anti-Pd-1/Pd-L1 Resistant Advanced Non-Small Cell Lung Cancer

April 24 (Reuters) - CHECKMATE PHARMACEUTICALS:

* CHECKMATE PHARMACEUTICALS ANNOUNCES START OF PHASE 1B TRIAL OF CMP-001 IN COMBINATION WITH ANTI-PD-L1 IMMUNOTHERAPY IN ANTI-PD-1/PD-L1 RESISTANT ADVANCED NON-SMALL CELL LUNG CANCER Source text for Eikon: (Reuters.Briefs@thomsonreuters.com)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below